SCHEMBL5498028

SCHEMBL5498028

CC(=O)Nc1cc(NC(=O)c2ccc(C)c(-c3ccc4nc(NCCCN5CCOCC5)ncc4c3)c2)ccc1F

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.69
RIPK3 Q9Y572 1/20 0.69
MAPK14 Q16539 14/20 0.69
LCK P06239 12/20 0.69
KDR P35968 11/20 0.69
JAK3 P52333 6/20 0.69
MAPK9 P45984 2/20 0.67
MAPK10 P53779 2/20 0.67
SRC P12931 1/20 0.67
TYK2 P29597 1/20 0.67
SYK P43405 1/20 0.67
MAPK8 P45983 1/20 0.67
BTK Q06187 1/20 0.67
KIT P10721 1/20 0.63
BRAF P15056 4/20 0.51
CDK1 P06493 1/20 0.47
CCNB1 P14635 1/20 0.47
CCNA2 P20248 1/20 0.47
CDK2 P24941 1/20 0.47
DDR2 Q16832 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5494933 0.88 LCK (0.77) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL14568856 0.88 RIPK1 (0.63) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL21402139 0.88 RIPK1 (0.63) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5502153 0.88 RIPK1 (0.63) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5494152 0.86 RIPK1 (0.76) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5497561 0.84 RIPK1 (0.68) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5490664 0.84 LCK (0.79) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5497137 0.83 RIPK1 (0.68) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5490376 0.83 RIPK1 (0.72) RIPK1RIPK3MAPK14LCKKDR
SCHEMBL5497868 0.83 RIPK1 (0.66) RIPK1RIPK3MAPK14LCKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP claimed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP claimed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US claimed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO claimed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 RIPK1 653/4885RIPK3 494/4885MAPK14 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.